Imaging experimental atherosclerotic lesions in ApoE knockout mice: Enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively charged polymers

Journal of Nuclear Medicine

Volumn 47, Issue 5, 2006, Pages 868-876

  Khaw, Ban An ^a   Tekabe, Yared ^a,b   Johnson, Lynne L ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Bispecific antibody; Pretargeting; Radiolabeled polymer

Indexed keywords

ANTIBODY; APOLIPOPROTEIN E; IMMUNOGLOBULIN F(AB) FRAGMENT; PENTETATE TECHNETIUM TC 99M; PENTETATE TECHNETIUM TC 99M SUCCINYL POLYLYSINE; POLYMER; UNCLASSIFIED DRUG; Z2D3 ANTIBODY; BISPECIFIC ANTIBODY; CHELATING AGENT; CROSS LINKING REAGENT; PENTETIC ACID; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL MODEL; FEMALE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; FEMORAL ARTERY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIBODIES, BISPECIFIC; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHELATING AGENTS; CROSS-LINKING REAGENTS; FEMALE; FEMORAL ARTERY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; PENTETIC ACID; POLYMERS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 33745525277     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science. 1985;229:81-83.
2. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugate: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
3. Le Doussal JM, Gruaz-Guyon A, Martin M, et al. Targeting of indium-111-labeled bivalent hapten to human melanoma by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 1990;50:3445-3452.
4. 188Re-labeled peptide. Bioconjug Chem. 2000;11:842-854.
5. Narula J, Petrov A, Ditlow C, et al. Maximizing radiotracer delivery to experimental atherosclerotic lesions with high-dose, negative charge-modified Z2D3 antibody for immunoscintigraphic targeting. J Nucl Cardiol. 1997;4:226-233.
6. 2 specific for the proliferating smooth muscle cells for human atheroma. Circulation. 1995;92:474-484.
7. Rousseaux J, Rousseaux-Prevost R, Bazin H. Optimal conditions for the preparation of proteolytic fragments from monoclonal IgG of different rat IgG subclasses. Methods Enzymol. 1986;121:663-669.
8. Bush DA, Winkler MA. Isoelectric focusinig of cross-linked monoclonal antibody heterodimers, homodimers, and derivatized monoclonal antibodies. J Chromatogr. 1989;489:303-311.
9. Khaw BA, Rammohan R, Abu-Taka A. Bispecific enzyme-linked signal-enhanced immunoassay with subatto-moles sensitivity. Assay Drug Dev Technol. 2005;3:319-327.
10. Ditlow CC, Chen FW, Calenoff E, inventors. Charter Ventures, assignee. Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof. US patent 5 811 248. September 22, 1998.
11. Ditlow CC, Chen FW, Calenoff E, inventors. Charter Ventures, assignee. Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof. US patent 5 955 584. September 21, 1999.
12. Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem. 1966;14:328-336.
13. Roque M, Fallon JT, Badimon JJ, et. al. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol. 2000; 20:335-342.
14. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262-1275.
15. Thomas WA, Reiner JM, Florentin RA, Lee KT, Lee WM. Population dynamics of arterial smooth muscle cells. V. Cell proliferation and cell death during initial 3 months in atherosclerotic lesions induced in swine by hypercholesterolemic diet and intimal trauma. Exp Mol Pathol. 1976;24:360-374.
16. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells) and may contribute to the accumulation of gruel and plaque instability. Am J Pathol. 1996;149:367-380.
17. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation. 2001;103:934-940.
18. Yee KO, Schwartz SM. Why atherosclerotic vessels narrow: the fibrin hypothesis. Thromb Haemost. 1999;82:762-771.
19. Geary RL, Nikkari ST, Wagner WD, et al. Wound healing: a paradigm for lumen narrowing after arterial reconstruction. J Vasc Surg. 1998;27:96-106.
20. Harrison DC, Calenoff E, Chen FW, Parmley WW, Khaw BA, Ross R. Plaque-associated immune reactivity as a tool for the diagnosis and treatment of atherosclerosis. Trans Am Clin Climatol Assoc. 1992;103:210-217.
21. 111In-Z2D3 on SPECT imaging in a swine model of coronary stent restenosis correlated with cell proliferation. J Nucl Med. 2004;45:294-299.
22. Carrio I, Pieri PL, Narula J, et al. Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells. J Nucl Cardiol. 1998;5:551-557.
23. 99mTc-glucarate for the necrotic myocardium: in vivo and in vitro assessment. J Nucl Cardiol. 1997;4:283-290.
24. Van Schaijk FG, Boekema M, Oossterwijk E, et al. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. J Nucl Med. 2005;46:10161022.